Skip To Main Content
Laura Bonanno on Muck Rack

Laura Bonanno

As seen in: Nature, MDPI, The New England Journal of Medicine, Lung Cancer, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Laura

Contact Laura, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial - Nature Medicine

|
By Tina Cascone, Laura Bonanno, Florian Guisier, Amelia Insa, Moishe Liberman, Olivier Bylicki, Lorenzo Livi, Thomas Egenod, Romain Corre, Dong-Wan Kim, Mariano Provencio Pulla, Byoung Yong Shim, Agata A. Bielska, Alula Yohannes, Yun He, Adam Dowson, Gozde Kar, Lara McGrath, Rakesh Kumar, Italia Grenga, Jonathan Spicer Verified
| Nature Verified
Abstract In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (Arm 2), or neoadjuvant durvalumab plus single-agent platinum chemotherapy with the TROP-2 antibody–drug conjugate (ADC) datopotamab deruxtecan (Arm 4), followed by surgical resection and...
Open in Who Shared Issue with article?

Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting

|
By Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, Laura Bonanno
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Secondary prevention and treatment innovation of early stage Non-Small Cell Lung Cancer: impact on diagnostic-therapeutic pathway from a multidisciplinary perspective

|
By Giulia Pasello, Daniela Scattolin, Laura Bonanno, Francesca Caumo
| Cancer Treatment Reviews Verified
Introduction Lung cancer (LC) is the second incident solid tumor and the first cause of cancer-related death worldwide, with more than two million new cases and about 1.800.000 deaths in 2020[ [1] Siegel R.L. Miller K.D. Fuchs H.E. Cancer statistics, 2022. ]. In Italy, more than 41.000 new cases have been estimated in 2020 with about 34.000 cancer-related deaths estimated in 2021[ [2] AIOM - AIRTUM; i numeri del cancro in Italia 2021.
Open in Who Shared Issue with article?
See all 4 licensed articles (5 Total)